

March 29, 2018
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

**Notice of Board of Director, Audit & Supervisory Board,
and Corporate Officer Appointments**

TOKYO, Japan, March 29, 2018 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to Symbio's Board of Directors and Audit & Supervisory Board (including appointment of a substitute member of the Audit & Supervisory Board) made by shareholder resolutions approved at the 13th Ordinary General Meeting of Shareholders, and Representative Director and Corporate Officer appointments approved by the Board of Directors at a board meeting convened following the close of the shareholders meeting. The appointments are as follows:

1. Members of the Board of Directors

Name	Title
Fuminori Yoshida	Representative Director
Kazuo Asakawa	Representative Director
Shigetoshi Matsumoto (newly appointed)	Outside Director
George Morstyn	Outside Director
Milton Grannatt	Outside Director
Robin Campbell (newly appointed)	Outside Director

- * Mr. Sumio Ariyoshi and Ms. Naoko Iino resigned upon expiration of their respective terms of office at the closing of the 13th Ordinary General Meeting of Shareholders held on March 29, 2018.

2. Member of the Audit & Supervisory Board

Name	Title
Kesao Endo (newly appointed)	Audit & Supervisory Board Member (outside member)

- * Mr. Shigetoshi Matsumoto resigned at the closing of the 13th Ordinary General Meeting of Shareholders held on March 29, 2018.

3. Substitute Member of the Audit & Supervisory Board

Name	Title
Takashi Watanabe	Substitute Member of the Audit & Supervisory Board

4. Corporate Officers

Name	Title
Fuminori Yoshida	Corporate Officer, President and Chief Executive Officer
Kazuo Asakawa	Corporate Officer, Executive Vice President and Chief Operating Officer
Tsutomu Abe	Corporate Officer
Kenji Murata	Corporate Officer

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125